摘要
All correspondence relating to this paper should be sent to: [email protected] As the new editor in chief (EiC) of the European Heart Journal—Valvular and Structural Heart Disease (EHJ-VSHD), Marco Metra is uniquely placed to advance the journal’s mission. Prof. Metra brings decades of clinical research and experience to the task of disseminating cutting-edge knowledge and science. He is currently the director of the Institute of Cardiology at the Civil Hospital and University of Brescia, Italy, and takes up a senior clinical academic role at the Vita-Salute University, San Raffaele Hospital in Milan, Italy, as of October 2025 (Figure 1). Prof. Marco Metra, MD, new editor in chief of the Journal of Valvular and Structural Heart Disease (EHJ-VSHD) The new journal—launched to address a growing trend in cardiology—was officially unveiled in Madrid, Spain, at the 2025 European Society of Cardiology (ESC) Congress. The impetus for the new publication, Prof. Metra says, came from his previous experience as EiC of the European Journal of Heart Failure (EJHF) between 2015 and 2023. ‘During those years, I noticed a rise in submissions related to valvular and structural heart disease. The focus of many of these articles was not necessarily directly related to heart failure, but to its cause, diagnosis, prognosis, and treatment. I became convinced that these were major areas of interest and it was time to give them their own journal.’ Prof. Metra’s main scientific focus has always been on heart failure which he first encountered when investigating cardiopulmonary exercise testing, followed by beta-blocker therapy and then acute heart failure. He has participated in and coordinated single- and multicentre trials of beta-blocker therapies, as well as the treatment of acute heart failure. More recently, he realized that a major change in the epidemiology of heart failure had taken place. ‘While heart failure was once primarily caused by coronary artery disease and heart attacks, now with improved acute coronary care and an ageing population, we have a situation that has made valvular heart disease a major contributor to heart failure,’ he says. He also notes that transcatheter treatment of valvular heart disease and progress in diagnosis and medical therapy of cardiomyopathies have opened up new indications for patients previously left with no treatment options. The changing epidemiology of heart failure also reflects improved diagnostics that now identify more cardiomyopathy patients, particularly those with cardiac amyloidosis. As major diagnostic and therapeutic advances are now available for both amyloidosis and hypertrophic cardiomyopathy, he says that the field needs to evolve with a focus on cardiovascular therapy moving towards personalised medicine. Prof. Metra describes his time as EiC of the EJHF as among the most satisfying and rewarding periods of his academic career. During this time, the journal became ranked among the top publications for cardiovascular disease. His tenure coincided with the COVID-19 pandemic—a testing time for scientific journals that had to respond with accuracy and clarity to an unprecedented global challenge. This critical event, he says, required leadership and scientific excellence such as that demonstrated by the EJHF, which published early authoritative papers on heart failure and hospitalisations that occurred during the pandemic. He believes this was a major achievement and reflects the duty of an EiC to identify major areas of interest, publish articles that become the reference for others, and anticipate changes ahead of everyone else. The time is now right for a new journal to tackle valvular and structural heart disease, Prof. Metra feels. ‘Our journal will remain focused on these diseases, including their epidemiology, pathophysiology, diagnosis and therapy, rather than on technical aspects and/or their late manifestations, such as arrhythmias or heart failure. Maybe in the near future we will be able to prevent the development of valvular heart disease with specific medications and our journal may be among the first to publish these data. We aim not only to look beyond, but also prior to, the indications and effects of interventional therapies, a hugely progressing field in cardiology. When you have a therapy and something to propose to the patient, there is always an increase in interest about the condition.’ The new journal will focus on three main areas: valvular heart disease, including aortic, mitral, and tricuspid valves; adult congenital heart disease; and remaining structural heart diseases, including amyloid cardiomyopathy, hypertrophic cardiomyopathy, and conditions such as patent foramen ovale, or left atrial auricular thrombosis. Some of these conditions, such as grown-up congenital heart disease, have become major epidemiological problems, but are nevertheless underrepresented in the current literature. He believes that the rise of new diagnostic tools and new treatment options—either medical therapy or transcatheter treatment—has prompted an impressive rise in translational and clinical research with lots of data deserving publication. As the author of over 1200 papers, Prof. Metra is well qualified to identify a good manuscript. ‘In general, journals are still ranked by citations of their articles,’ he says. ‘This is measured as their Impact Factor (IF) or similar, and I agree that the IF value of a scientific article can be related to the number of times it is cited.’ As EiC, he enjoys being able to predict the citation potential of an article, but observes there are exceptions to IF metrics. ‘For instance, an article may be so far ahead of its time that it may be more widely cited 5–10 years later.’ Other ways of assessing impact such as the Altmetric Attention Score—alternative metrics that measure the impact of papers on social media, news outlets, and policy are also vital and possibly more important than the scientific impact alone, he says. ‘Additionally, we have introduced so-called “how to” papers to help clinicians handle challenging medical problems. With these articles, the number of downloads may be a more accurate measurement of their impact.’ Prof. Metra believes that topic interest and the relative novelty of the article—coupled with robust methodology and results that support the conclusions—is what matters when ranking the value of a submitted article and taking a decision on its publication. The role of EiC, he says, provides unique opportunities to shape future directions for research and to decide what is important—and what is not—from submitted articles. ‘It gives you the opportunity to build an editorial board, gather a high-ranking scientific community able to discuss the newest advances in research and take the best decisions. Scientific journals are the essence of scientific research, and the editorial board becomes the place where friendship, mutual trust, and authority allow the journal to grow and the possibility to offer our patients better options for their health and well-being.’ All authors declare no disclosure of interest for this contribution.